1. Home
  2. SGRY vs FOLD Comparison

SGRY vs FOLD Comparison

Compare SGRY & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGRY
  • FOLD
  • Stock Information
  • Founded
  • SGRY 2004
  • FOLD 2002
  • Country
  • SGRY United States
  • FOLD United States
  • Employees
  • SGRY N/A
  • FOLD N/A
  • Industry
  • SGRY Hospital/Nursing Management
  • FOLD Biotechnology: Pharmaceutical Preparations
  • Sector
  • SGRY Health Care
  • FOLD Health Care
  • Exchange
  • SGRY Nasdaq
  • FOLD Nasdaq
  • Market Cap
  • SGRY 2.8B
  • FOLD 2.9B
  • IPO Year
  • SGRY 2015
  • FOLD 2007
  • Fundamental
  • Price
  • SGRY $22.68
  • FOLD $6.08
  • Analyst Decision
  • SGRY Buy
  • FOLD Buy
  • Analyst Count
  • SGRY 8
  • FOLD 10
  • Target Price
  • SGRY $35.43
  • FOLD $16.22
  • AVG Volume (30 Days)
  • SGRY 890.8K
  • FOLD 4.6M
  • Earning Date
  • SGRY 05-12-2025
  • FOLD 05-01-2025
  • Dividend Yield
  • SGRY N/A
  • FOLD N/A
  • EPS Growth
  • SGRY N/A
  • FOLD N/A
  • EPS
  • SGRY N/A
  • FOLD N/A
  • Revenue
  • SGRY $3,114,300,000.00
  • FOLD $543,141,000.00
  • Revenue This Year
  • SGRY $10.88
  • FOLD $21.87
  • Revenue Next Year
  • SGRY $9.21
  • FOLD $22.19
  • P/E Ratio
  • SGRY N/A
  • FOLD N/A
  • Revenue Growth
  • SGRY 13.52
  • FOLD 28.25
  • 52 Week Low
  • SGRY $19.50
  • FOLD $6.20
  • 52 Week High
  • SGRY $33.97
  • FOLD $12.65
  • Technical
  • Relative Strength Index (RSI)
  • SGRY 52.98
  • FOLD 29.58
  • Support Level
  • SGRY $21.30
  • FOLD $6.63
  • Resistance Level
  • SGRY $23.63
  • FOLD $7.71
  • Average True Range (ATR)
  • SGRY 0.61
  • FOLD 0.30
  • MACD
  • SGRY 0.27
  • FOLD -0.05
  • Stochastic Oscillator
  • SGRY 75.52
  • FOLD 13.76

About SGRY Surgery Partners Inc.

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: